1)van der Bruggen P, et al : A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 : 1643─1647, 1991
2)Zhang L, et al : Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. Engl J Med 348 : 203─213, 2003
3)Hwang WT, et al : Prognostic significance of tumor-infiltrating T cells in ovarian cancer : a meta-analysis. Gynecol Oncol 124 : 192─198, 2012
4)Heong V, et al : Update on immune checkpoint inhibitors in gynecological cancers. J Gynecol Oncol 28 : e20, 2017
5)Hamanishi J, et al : Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33 : 4015─4022, 2015
6)Grupp SA, et al : Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368 : 1509─1518, 2013
7)Rodriguez-Garcia A, et al : T-cell target antigens across major gynecologic cancers. Gynecol Oncol 145 : 426─435, 2017
8)van Vloten JP, et al : Critical interactions between immunogenic cancer cell death, oncolytic viruses, and the immune system define the rational design of combination immunotherapies. J Immunol 200 : 450─458, 2018
9)Andtbacka RH, et al : Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33 : 2780─2788, 2015
10)Hasegawa K, et al : Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 12 : 1868─1875, 2006
11)Galanis E, et al : Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res 75 : 22─30, 2015